ORC2

Across TCGA pan-cancer cohorts, ORC2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ORC2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ORC2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ORC2 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM, PDAC, and CCRCC are the cancer types where ORC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.578	0.306	.008	13	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	6	view →
CCRCC	DFS	Tertile	All	0.656	1.000	.032	4	view →
HNSC	OS	Quartile	All	0.734	0.905	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ORC2–GBM (OS)

Open the GBM breakdown →